+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: K562, 293T and A549 cell lysates, Primary antibody: P09660(MAGEA11 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09660(MAGEA11 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The MAGE-A11 antibody is a crucial tool for studying the melanoma-associated antigen A11. a member of the MAGE (melanoma antigen gene) family. MAGE proteins are cancer-testis antigens, typically expressed in germ cells and placenta but silenced in most somatic tissues. Their re-emergence in cancers, including melanoma, lung, prostate, and ovarian tumors, links them to oncogenesis and makes them potential immunotherapy targets. MAGE-A11. specifically, is implicated in transcriptional regulation, cell cycle progression, and apoptosis evasion. It interacts with androgen receptors (AR), enhancing their transcriptional activity, which may drive prostate cancer progression and resistance to therapies.

Antibodies targeting MAGE-A11 enable researchers to detect its expression in tissues or cell lines via techniques like immunohistochemistry (IHC), Western blot, or immunofluorescence. These antibodies are vital for understanding MAGE-A11’s role in tumor biology, prognostic significance, and its utility as a diagnostic or therapeutic biomarker. However, developing specific MAGE-A11 antibodies is challenging due to high homology among MAGE family members. Validated antibodies are essential to avoid cross-reactivity and ensure accurate experimental outcomes. Recent studies also explore MAGE-A11’s potential in adoptive T-cell therapies or cancer vaccines, underscoring the antibody’s importance in both basic research and clinical applications.